MARINOMED

Marinomed is a biopharmaceutical development company focusing on the development of innovative therapies based on patent protected technology platforms. Products against respiratory viruses derived from the proprietary MAVIREX platform are marketed with renowned partners in a growing number of countries around the globe. The new MARINOSOLV platform allows novel stable aqueous formulations of hardly soluble compounds such as corticosteroids, enabling a faster onset of action and a better bioavailability. The MARINOSOLV technology is not limited to a specific compound and has the potential to facilitate delivery of any compound with solubility issues. Marinomed was founded on 2006 and is headquartered in Vienna, Austria.